| |
Latest 10 SEC filings (by transaction date) for XFOR within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Mar 11/24 | Mar 11/24 | Taveras Arthur | Direct Ownership | Common Stock | S - Open market or private sale | -14,235 | $0.882 |
Mar 11/24 | Mar 11/24 | Ragan Paula | Direct Ownership | Common Stock | S - Open market or private sale | -49,678 | $0.883 |
Mar 11/24 | Mar 11/24 | Mostafa Adam S. | Direct Ownership | Common Stock | S - Open market or private sale | -52,500 | $0.883 |
Mar 11/24 | Mar 11/24 | DiBiase Mary | Direct Ownership | Common Stock | S - Open market or private sale | -15,409 | $0.882 |
Feb 28/24 | Feb 13/24 | Arbet-Engels Christophe | Direct Ownership | Stock Appreciation Right | A - Grant, award or other under Rule 16b-3(d) | 180,816 | |
Feb 16/24 | Feb 13/24 | Arbet-Engels Christophe | Direct Ownership | Stock Appreciation Right | A - Grant, award or other under Rule 16b-3(d) | 475,831 | |
Feb 16/24 | Feb 13/24 | Mostafa Adam S. | Direct Ownership | Stock Appreciation Right | A - Grant, award or other under Rule 16b-3(d) | 523,414 | |
Feb 16/24 | Feb 13/24 | DiBiase Mary | Direct Ownership | Stock Appreciation Right | A - Grant, award or other under Rule 16b-3(d) | 428,248 | |
Feb 16/24 | Feb 13/24 | Ragan Paula | Direct Ownership | Stock Appreciation Right | A - Grant, award or other under Rule 16b-3(d) | 1,189,578 | |
Feb 16/24 | Feb 13/24 | Baldry Mark | Direct Ownership | Stock Appreciation Right | A - Grant, award or other under Rule 16b-3(d) | 523,414 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for XFOR within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Mar 11/24 | Mar 11/24 | Taveras Arthur | Direct Ownership | Common Stock | S - Open market or private sale | -14,235 | $0.882 |
Mar 11/24 | Mar 11/24 | Ragan Paula | Direct Ownership | Common Stock | S - Open market or private sale | -49,678 | $0.883 |
Mar 11/24 | Mar 11/24 | Mostafa Adam S. | Direct Ownership | Common Stock | S - Open market or private sale | -52,500 | $0.883 |
Mar 11/24 | Mar 11/24 | DiBiase Mary | Direct Ownership | Common Stock | S - Open market or private sale | -15,409 | $0.882 |
Feb 28/24 | Feb 13/24 | Arbet-Engels Christophe | Direct Ownership | Stock Appreciation Right | A - Grant, award or other under Rule 16b-3(d) | 180,816 | |
Feb 16/24 | Feb 13/24 | Arbet-Engels Christophe | Direct Ownership | Stock Appreciation Right | A - Grant, award or other under Rule 16b-3(d) | 475,831 | |
Feb 16/24 | Feb 13/24 | Mostafa Adam S. | Direct Ownership | Stock Appreciation Right | A - Grant, award or other under Rule 16b-3(d) | 523,414 | |
Feb 16/24 | Feb 13/24 | DiBiase Mary | Direct Ownership | Stock Appreciation Right | A - Grant, award or other under Rule 16b-3(d) | 428,248 | |
Feb 16/24 | Feb 13/24 | Ragan Paula | Direct Ownership | Stock Appreciation Right | A - Grant, award or other under Rule 16b-3(d) | 1,189,578 | |
Feb 16/24 | Feb 13/24 | Baldry Mark | Direct Ownership | Stock Appreciation Right | A - Grant, award or other under Rule 16b-3(d) | 523,414 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Neurocrine Biosciences (OQ:NBIX) |
Regeneron Pharmaceuticals (OQ:REGN) |
Madrigal Pharmaceuticals (OQ:MDGL) |